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Objectives: The purpose of this study was to estimate the costs of immune-related adverse events 
(irAEs) associated with the new anti-PD1 immuno-oncology therapies, with the anti-CTLA-4 
immuno-oncology therapy and with the combined therapy (CTLA4 + anti-PD1) in patients affected 
by metastatic melanoma. 
Materials and methods: A probabilistic cost of illness (COI) model has been developed to estimate 
the management costs of grade ≥ 3 adverse events associated with the new anti-PD1 therapies 
(pembrolizumab and nivolumab), the anti-CTLA-4 therapy (ipilimumab) and the combined therapy 
CTLA4 + anti-PD1 (nivolumab + ipilimumab) for the treatment of patients with metastatic melanoma 
from the National Health Service (NHS) perspective in Italy. The identification of the 
epidemiological and cost parameters to be included in the cost of illness model was carried out 
through a systematic literature review (SLR). Univariate and probabilistic sensitivity analyses were 
conducted to verify the sensitivity of the model results. 
Results: The model has estimated a cost associated with the management of grade ≥ 3 immune-
related adverse events in patients with metastatic melanoma equal to €176.2 (95% CI: €63.5-€335.0) 
for anti-CTLA-4 therapy, €48.6 (95% CI: €40.1-€58.5) for the new anti-PDI therapies, and €276.8 
(95% CI: €240.4-€316.2) for the combined therapy. Among the innovative therapies for the 
considered metastatic melanoma, the combined therapy was the most expensive innovative treatment 
in terms of event management of immune-related grade ≥ 3 adverse events. 
Conclusion: This study may represent a useful tool to understand the economic burden associated 
with the management of irAEs associated with patients affected by metastatic melanoma. 
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Key-Point 
Firstly, to our knowledge, the present study represents the first attempt to evaluate the economic 
dimension on the toxicity linked to the immuno-oncology therapies in patients affects by metastatic 
melanoma and this represents an essential element to evaluate the cost-effectiveness associated with 
an innovative drug.  
Secondly, a lot of economic evaluation conducted in Italy seems to be heterogeneous in terms of 
economic safety aspects and we tried to summarise all the literature information in order to inform 
the decision makers regarding the additional costs needed for the treatment of severe adverse  
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Introduction 
With the advent of new immuno-oncology treatments, the approach to patients affected by 
advanced melanoma has changed considerably, significantly impacting, from a statistical point of 
view, the survival of patients with advanced/metastatic melanoma. 
The anti-CTLA-4 and anti-PD-1 antibodies oppose the blockade of immune “checkpoints” 
and have been approved for the treatment of advanced melanoma. Ipilimumab, an anti-CTLA-4 drug 
approved in 2011, was the first immuno-oncology drug for the treatment of advanced melanoma [1]. 
Nivolumab and pembrolizumab are additional immuno-oncology monotherapy drugs that are 
available for the treatment of advanced melanoma. These are monoclonal antibodies that promote the 
anticancer activity mediated by T lymphocytes and oppose the PD-1 co-inhibitory molecule. 
The most prominent evidence regarding the use of immune checkpoint inhibitors comes from 
studies on advanced melanoma [2]. The use of ipilimumab [3, 4], nivolumab [5, 6] and 
pembrolizumab [7, 8] has resulted in improved survival compared with cytotoxic chemotherapy, both 
for pre-treated and naive patients. Furthermore, the combined immunotherapy with nivolumab and 
ipilimumab results in a higher response rate and a longer progression time compared with the action 
of ipilimumab alone [9]. Considering the success of immune checkpoint inhibitors, these agents may 
be a basic component of a therapeutic strategy using checkpoint inhibitors in combination or with 
other anticancer agents [10, 11]. However, when therapeutic strategies use a combination of drugs, 
toxicity could be a limiting factor. Therefore, early recognition and a methodical design of a baseline 
and adverse event management assessment are fundamental to the success of the treatment [10]. 
Many of the possible side effects of the new immunotherapy drugs are strictly linked with 
their specific mechanism of action [1]. Additionally, the immune system stimulation used to fight 
cancer may also trigger unwanted processes of autoimmune-like reactions [1]. So-called immune-
related toxicity represents a secondary toxicity to an autoimmune-like reaction during treatment with 
immunotherapy drugs [1]. Such toxicity may take place anytime during the treatment and may involve 
many different organs [1], among which are the skin, the gastrointestinal tract, the liver and the 
endocrine system (thyroid, pituitary gland), in order of median time to onset [2]. These side effects 
are normally manageable, but in some cases, they may be lethal [3, 7, 12, 13]. 
The objective of this work was to estimate the costs of grade ≥ 3 irAEs that are associated 
with new anti-PD1 therapies (pembrolizumab and nivolumab), with anti-CTLA-4 (ipilimumab) 
therapy and with the combined therapy CTLA4 + anti-PD1 (nivolumab + ipilimumab) in patients 
affected by metastatic melanoma. 
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Methods 
Study design 
 
 
 
A probabilistic incidence-based cost of illness model was developed to estimate the aggregate 
measure of the economic impact of grade ≥ 3 irAEs (severe, life-threatening or disabling irAE) of 
immune-oncology therapies for the treatment of patients with metastatic melanoma. 
The analysis was conducted from the National Health Service (NHS) perspective in Italy, and 
only direct health costs over a one-year time horizon from the beginning of therapy were considered. 
The identification of the epidemiological and cost parameters to be included in the model was carried 
out through a systematic literature review (SLR) of available studies. For each treatment, the model 
calculated the cost associated with the irAE for each treatment by multiplying each incidence estimate 
by the respective adverse event cost. 
Finally, deterministic and probabilistic sensitivity analyses were performed in order to take 
into account the variability of the data used in the model. 
 
A systematic literature review (SLR) of the available literature was carried out through a 
systematic method aimed at identifying the epidemiological and cost data related to the irAEs 
associated with anti-PD1, anti-CTLA-4 and combined therapies for the treatment of metastatic 
melanoma. The search was carried out through the MEDLINE electronic database (PubMed) for 
English and Italian articles. Moreover, to identify further national literature, an analysis of Italian 
grey literature was performed by consulting non-indexed peer reviewed scientific magazines on 
PubMed that examined the health economics aspects connected with the research being analysed in 
this work and in-line with the objectives of the study.  
 To identify the parameters required to build the model, this research was conducted by 
pursuing two different objectives. The first objective was to identify the epidemiological and 
incidence data of the adverse events associated with the anti-PD1, anti-CTLA-4 and combined 
therapies (CTLA4 + anti-PD1). The second objective was focused on the search of the cost data 
associated with the management of these adverse events following the treatments being analysed. In-
line with the guidelines for the systematic analysis of the scientific literature, figure 1 shows the 
systematic process used to carry out the search. The systematic process comprised 4 stages: 
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identification, screening, eligibility and inclusion. The search code used to identify the 
epidemiological parameters was as follows: 
("Metastatic Melanoma"[Title/Abstract]) AND (“nivolumab”[Title/Abstract] OR 
“ipilimumab”[Title/Abstract] OR “pembrolizumab”[Title/Abstract] OR “combined 
immunotherapy”[Title/Abstract]) AND (“safety”[Title/Abstract] OR “safety melanoma 
treatment”[Title/Abstract] OR “Adverse event”[Title/Abstract] OR “Adverse 
events”[Title/Abstract] OR “Adverse events”[Mesh] OR "Drug-Related Side Effects and Adverse 
Reactions"[Mesh]).  
With reference to cost data, the search code was the same as that used to identify the 
epidemiological parameters but included the following search extensions aimed at identifying the 
cost parameters: (“Economic burden”[Title/Abstract] OR “Cost of illness”[Title/Abstract] OR 
“costs”[Title/Abstract] OR “cost”[Title/Abstract]). Regarding the Italian scientific magazines, the 
articles were identified through the keyword “metastatic melanoma”. By means of the above 
mentioned search codes, 366 articles in the MEDLINE electronic database were identified, while 
articles from other sources were identified after reading the articles found through the electronic 
database. 
The eligibility criteria used to determine whether an article would be included in the cost of 
illness model were as follows: 
 
- phase III clinical trial conducted on patients with metastatic melanoma to whom at least 
one of the innovative treatments considered in the search was administered, according to 
the dose indicated in the technical sheet (ipilimumab: 3 mg/kg every 3 weeks; nivolumab 
3 mg/kg every 2 weeks; pembrolizumab: 2 mg/kg every 3 weeks; nivolumab/ipilimumab: 
1 mg/kg of nivolumab + 3 mg/kg of ipilimumab every 3 weeks); 
- review/retrospective study conducted on patients with metastatic melanoma to whom at 
least one of the innovative treatments considered in the search was administered, 
according to the dose indicated in the technical sheet (ipilimumab: 3 mg/kg every 3 weeks; 
nivolumab 3 mg/kg every 2 weeks; pembrolizumab: 2 mg/kg every 3 weeks; 
nivolumab/ipilimumab: 1 mg/kg of nivolumab + 3 mg/kg of ipilimumab every 3 weeks); 
- article containing cost data, in the Italian National Health Service context. 
 
The articles that did not meet these eligibility criteria were excluded. At the end of this 
systematic process, 16 articles in total were included in the model; 14 referred to epidemiological 
data and 2 referred to cost data. The articles related to the epidemiological data referred to 5 phase III 
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clinical trials [3, 5-7, 9] that were conducted on patients with phase III or IV unresectable melanoma, 
who submitted to at least one of the innovative treatments considered in the analysis, 8 retrospective 
studies [14-21] and 1 review [22]. 
 
Figure 1 - PRISMA Flow Diagram  
 
Epidemiological parameters 
The epidemiological parameters referred to the incidence estimates of grade ≥ 3 adverse 
events that were associated with anti-PD1, anti-CTLA-4 and combined therapies (according to the 
doses indicated in the technical sheet) administered to treat patients affected by metastatic melanoma. 
The estimates obtained from the literature are shown in tables 1, 2 and 3. Most of the studies included 
in the analysis that emerged from the systematic literature review involved anti-CTLA-4 therapy 
(ipilimumab) (Table 2), while only 2 articles were included that studied nivolumab + ipilimumab 
combination [9] or anti-PD1 pembrolizumab therapy [7]. 
In particular, with reference to pembrolizumab, the clinical trial included in the analysis used 
an administration regimen in patients affected by metastatic melanoma equal to 10 mg/kg every 2 or 
3 weeks. Even if this regimen does not correspond to that indicated in the technical sheet, in the 
randomized phase I (KEYNOTE-001) and phase II (KEYNOTE-002) clinical trials, the 
administration of pembrolizumab corresponding to doses ranging from 2 mg/kg every 3 weeks to 10 
mg/kg every 2 weeks did not influence the results [23-26].  
Among all the grade ≥ 3 irAEs considered in the analysis, the highest incidence estimates 
were those corresponding to the combination therapy. 
With reference to the grade ≥ 3 immune-related adverse events of the skin, rash was the most 
widespread immune-related adverse event among the patients with metastatic melanoma, with an 
average incidence of 1.9% in patients treated with anti-CTLA-4 therapy, 0.5% in those treated with 
anti-PD1 immuno-oncology therapy and 4.8% in patients treated with the nivolumab/ipilimumab 
combination. In this specific case, the term rash includes both the rash adverse event and the 
maculopapular rash adverse event. Among the grade ≥ 3 gastrointestinal adverse events, diarrhoea 
was the most widespread immune-related adverse event in patients affected by metastatic melanoma 
treated with nivolumab/ipilimumab combination (9.3% of the patients suffer from this adverse event) 
and anti-PD1 therapies (on average, 1.1% of the patients suffered from this adverse event). Of these, 
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colitis also resulted in significant adverse events, especially in patients treated with the 
nivolumab/ipilimumab combination (7.7% of patients) and with anti-CTLA-4 therapy (incidence of 
0.8%). The grade ≥ 3 immune-related hepatic adverse events are particularly widespread in patients 
with metastatic melanoma treated with the nivolumab/ipilimumab combination. Of these patients, 
8.3% showed an increase in alanine aminotransferase, while 6.1% of the patients had an increase in 
aspartate aminotransferase. 
Among the grade ≥ 3 immune-related endocrine adverse events, the highest incidence estimate 
was detected for hypophysitis (on average, 1.6% of patients treated with anti-CTLA-4 therapy, 0.4% 
of patients treated with the new anti-PD1 immuno-oncology therapies and 1.6% of patients treated 
with the combination). 
Finally, even grade ≥ 3 pneumonia was particularly widespread among the patients with 
metastatic melanoma being treated with the combination (1% of patients). 
 
Table 1 – Grade ≥ 3 immune-related adverse events (irAEs) associated with anti-PD1 therapy 
(pembrolizumab, nivolumab) in patients affected by metastatic melanoma 
PEMBROLIZUMAB, 
NIVOLUMAB 
Robert et al. 2015 
[7] 
Weber JS et al. 
2015 [6] 
Larkin et al. 
2015 [9] 
Robert et al. 2015 
[5] 
Eigentler et al. 
2016 [22] 
Skin           
Pruritus 0.0% 0.0% 0.0% 0.5% 0.2% 
Rash 0.4% 0.4% 0.6% 0.5% 0.4% 
Vitiligo 0.0% 0.0% 0.3% 0.0%   
Gastrointestinal           
Diarrhoea 1.1% 0.4% 2.2% 1.0% 0.6% 
Colitis 1.8% 0.7% 0.6% 0.5% 0.6% 
Hepatic           
Increase in alanine 
aminotransferase 0.4% 0.7% 1.3% 1.0% 1.1% 
Increase in aspartate 
aminotransferase 0.4% 0.4% 1.0% 0.5% 0.6% 
Endocrine           
Hypothyroidism 0.0% 0.0% 0.0% 0.0% 0.0% 
Hyperthyroidism 0.0% 0.0% 0.0% 0.0% 0.2% 
Hypophysitis 0.4%   0.3% 0.5% 0.2% 
Pulmonary           
Pneumonia 0.4% 0.0% 0.3% 0.0%   
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Table 2 - Grade ≥ 3 immune-related adverse events (irAEs) associated with anti-CTLA-4 therapy 
(ipilimumab) in patients affected by metastatic melanoma 
IPILIMUMAB 
Hodi FS et 
al. 2010 
[3] 
Larkin et 
al. 2015 
[9] 
Wiater et 
al. 2013 
[14] 
Ahmad et 
al. 2015 
[15] 
Ascierto 
et al. 
2014 [16] 
Daly et al. 
2017 [20] 
Jung et al. 
2017 [17] 
Margolin 
et al. 
2015 [21] 
Robert et 
al. 2015 
[7] 
Del 
Vecchio 
et al. 
2014 [18] 
Sileni et 
al. 2014 
[19] 
Skin                       
Pruritus 0.0% 0.3% 0.0% 1.0% 0.9% 0.0% 1.0% 0.4% 0.4% 0.0% 0.0% 
Rash 0.8% 1.9% 0.0% 3.0% 0.9% 8.3% 1.0% 0.7% 1.2% 1.0% <1% 
Vitiligo 0.0% 0.0% 0.0%           0.0%     
Gastrointestinal                       
Diarrhoea 4.6% 6.1% 4.0% 13.0% 2.0% 4.8% 0.0% 1.5% 3.1% 4.0% 1.0% 
Colitis 5.3% 8.7%       6.0%   4.1% 6.3%     
Hepatic                       
Increase in alanine 
aminotransferase 0.0% 1.6%             0.8%     
Increase in aspartate 
aminotransferase 0.0% 0.6%             0.8%     
Endocrine                       
Hypothyroidism 0.0% 0.0% 0.0%     0.0%     0.0%     
Hyperthyroidism   0.0% 2.0%           0.4%     
Hypophysitis 1.5% 1.9% 2.0% 2.0%   1.2%     0.8%     
Pulmonary                       
Pneumonia   0.3%             0.4%     
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Table 3 - Grade ≥ 3 immune-related adverse events (irAEs) associated with the combined therapy 
(nivolumab + ipilimumab) in patients affected by metastatic melanoma. 
NIVOLUMAB/IPILIMUMAB Larkin et al. 2015 [9] 
Skin   
Itch 1.9% 
Rash 4.8% 
Vitiligo 0.0% 
Gastrointestinal   
Diarrhoea 9.3% 
Colitis 7.7% 
Hepatic   
Increase in alanine aminotransferase 8.3% 
Increase in aspartate aminotransferase 6.1% 
Endocrine   
Hypothyroidism 0.3% 
Hyperthyroidism 1.0% 
Hypophysitis 1.6% 
Pulmonary   
Pneumonia 1.0% 
Cost parameters 
The cost parameters included in the analysis refer to the costs associated with the management 
and treatment of adverse events in the patients affected by metastatic melanoma, following the 
administration of one of the above mentioned innovative treatments. Table 4 reports the cost estimates 
obtained from 2 studies through a systematic review of the literature carried out for some countries, 
including Italy, with the objective of estimating the economic burden of the adverse events associated 
with the treatment of metastatic melanoma [27, 28]. For the adverse event pneumonia, the model 
takes into account the national tariff associated with DRG 90 (simple pneumonia and pleurisy, age > 
17, without complications) [29]. The annual cost associated with the hepatic adverse events (increase 
in alanine aminotransferase and increase in aspartate aminotransferase), vitiligo, hypothyroidism and 
hyperthyroidism was obtained through the reconstruction of the therapeutic path and the monitoring 
of patients affected by each adverse event. The evaluation of specialist services was made through 
the national tariff of specialist care services [30]. 
Specifically, the cost of vitiligo was calculated taking into account the cost of a general specialist 
visit (Code 89.7). The costs associated with the increase in alanine aminotransferase and aspartate 
aminotransferase were obtained considering the cost of a general specialist visit and the specific blood 
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tests: an alanine aminotransferase test (ALT) (GPT) S/U (Code 90.04.5) for the increase in alanine 
aminotransferase and an aspartate aminotransferase test (AST) (GOT) S (Code 90.09.2) for the 
increase in aspartate aminotransferase. 
The cost associated with hyperthyroidism was assumed to be equal to the cost incurred for 3 general 
specialist visits, a head and neck sonogram (Code 88.71.4), 6 thyrotropine tests (TSH) (Code 90.42.1), 
6 free thyroxine tests (FT4) (Code 90.42.23) and 653 tablets of thiamazole (4-6 tablets a day for 4 
weeks + maintenance therapy of 1-2 tablets for 12-18 months). The cost associated with 
hyperthyroidism was calculated considering the cost incurred for a general specialist visit, 2 
thyrotropine tests (TSH) (Code 90.42.1), 2 free thyroxine tests (FT4) (Code 90.42.3) and 365 tablets 
of levothyroxine sodium (1 tablet per day). 
Table 4 – Costs associated with immune-related adverse events (irAEs) 
Adverse event Cost Source 
Pruritus (grade 1-2) € 11.26 [27] 
Rash (grade 3-4) € 1,355.00 [28] 
Vitiligo € 20.66 Specialist tariff (89.7: general visit) [30] 
Diarrhoea ( grade 3-4) € 1,486.00 [28] 
Colitis (grade 3-4) € 183.98 [27] 
 Increase in alanine aminotransferase € 21.66 
Specialist tariff (1 general visit [89.7] + 1 alanine 
aminotransferase test (ALT) (GPT) [S/U] [90.04.5]) [30] 
 
Increase in aspartate aminotransferase € 21.70 
Specialist tariff (1 general visit [89.7] + 1 aspartate 
aminotransferase test (AST) (GOT) [S] [90.09.2] 
 
Hypothyroidism € 64.16 
Specialist tariff (1 general visit [89.7] + 2 thyrotropine 
tests (TSH) [90.42.1] + 2 free thyroxine tests (FT4) 
[90.42.3]) [30], Farmadati (365 tablets of levothyroxine 
sodium) 
 
Hyperthyroidism € 230.83 
Specialist tariff (3 general visits [89.7] + 1 head and neck 
sonogram [88.71.4] + 6 thyrotropine tests (TSH) 
[90.42.1] + 6 free triodothyronine tests (FT3) [90.43.3] + 
6 free thyroxine tests (FT4) [90.42.3]) [30], Farmadati 
(653 thiamazole tablets)  
Hypophysitis (grade 3-4) € 1,915.00 [28] 
Pneumonia € 2,291.00 
DRG (simple pneumonia and pleurisy, age > 17 without 
complications) [29] 
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Sensitivity analysis 
To consider the variability of the data obtained through a systematic literature review, a cost 
of illness model was developed following a probabilistic approach (probabilistic sensitivity analysis 
– PSA). This probabilistic analysis considers all the estimates obtained from the literature, indicating 
the minimum and maximum values of the probabilistic distribution of each parameter considered in 
the analysis. In particular, the choice of the probabilistic distribution to be associated with each 
parameter was made according to the scientific literature on the development of the probabilistic 
models in the economic evaluations, thus attributing a beta distribution to each epidemiological 
parameter and a gamma distribution to each cost parameter [31]. 
Based on these probabilistic distributions, 1,000 Monte Carlo simulations were performed to 
generate a 95% confidence interval, in which each result obtained through a cost of illness model 
could be included. The variability associated with the anti-CTLA-4 and nivolumab immuno-oncology 
therapies corresponds to the minimum and maximum values found in the literature. With reference 
to pembrolizumab and the combination, the model assumed 25% variability, as only two studies were 
eligible in the literature, one for each treatment. 
Finally, a one-way deterministic sensitivity analysis was conducted to verify the sensitivity of 
the cost of illness model results compared to each parameter considered in the model. Such analysis 
consists of changing one parameter at a time, according to the minimum and maximum values found 
in the literature or assumed by the authors. In this specific case, the sensitivity analysis was conducted 
considering the minimum and maximum incidence estimates of the immune-related adverse events 
identified in the literature for the anti-CTLA-4 and anti-PD1 (Tables 1 and 2) therapies. For the 
combined therapy, the sensitivity analysis was conducted assuming ±25% variability corresponding 
to each adverse immune-related event. With reference to the cost estimate, the minimum and 
maximum values were defined assuming ± 25% variability. 
 
Results 
To estimate the costs associated with the management of grade ≥ 3 irAEs in patients affected 
by metastatic melanoma, the cost of illness model has specifically taken into account the articles of 
Larkin et al. and Robert et al., the former for grade ≥ 3 adverse events referring to nivolumab, 
ipilimumab and the combination, the latter for grade ≥ 3 adverse events referring to pembrolizumab. 
The incidence estimates of the irAEs associated with the new anti-PD1 therapies have been 
obtained as a simple average of the incidence estimates for pembrolizumab and nivolumab that have 
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emerged from the literature. The 95% confidence intervals were estimated considering the minimum 
and maximum values from the literature in the case of anti-PD1 and anti-CTLA-4 therapies, while 
for the combined therapy, the model has assumed 25% variation compared with the incidence 
estimates from the article by Larkin et al. [9] (the only article that emerged from the literature). The 
model estimated a cost associated with the management of grade ≥ 3 immune-related adverse events 
in patients affected by metastatic melanoma equal to €176.2 (95% CI: €63.5-€335.0) for anti-CTLA-
4 therapy, €48.6 (95% CI: €40.1-€58.5) for new anti-PDI immuno-oncology therapies, and €276.8 
(95% CI: €240.4-€316.2) for immuno-oncology combined therapy (table 5). Among the innovative 
therapies for metastatic melanoma, immuno-oncology combined therapy was the most expensive 
treatment in terms of event management of grade ≥ 3 irAEs. Because of the greatest variability related 
to the incidence in the literature, the model estimated a large confidence interval for anti-CTLA-4 
therapy. 
Table 5 – Average annual cost associated with the management of grade ≥ 3 irAEs in patients affected 
by metastatic melanoma treated with anti-CTLA-4 therapy, new anti-PD1 therapies and combined 
therapy. 
 
Anti-PD1 immuno-
oncology therapies 
(nivolumab, 
pembrolizumab) 
  
Anti-CTLA-4 immuno-
oncology therapy 
(ipilimumab) 
 
Immuno-oncology combined 
therapy  
(nivolumab + ipilimumab) 
Cost/patient € 48.6 € 176.2 € 276.8 
95% CI (€ 40.1-€ 58.5) (€ 63.5-€ 335.0) (€ 240.4-€ 316.2) 
 
Figures 2, 3 and 4 report the results of the one-way deterministic analysis conducted for each 
innovative treatment considered in this study. In particular, the annual cost associated with the 
management of grade ≥ 3 irAEs in a patient affected by metastatic melanoma treated with anti-CTLA-
4 therapy and immuno-oncology combined therapy was very sensitive to the variations in the event 
incidence towards colitis, while for new anti-PD1 therapies, such cost was very sensitive to the event 
incidence towards diarrhoea. 
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Figure 2 – Sensitivity deterministic analysis for anti-CTLA-4 therapy – tornado chart 
 
Figure 3 – Sensitivity deterministic analysis for anti-PD1 therapies – tornado chart 
 
Figure 4 – Sensitivity deterministic analysis for combined therapy (CTLA4 + anti-PD1) – tornado 
chart 
 
Discussion 
Immuno-oncology therapies represent a new treatment opportunity for patients affected by 
metastatic melanoma. However, in addition to the high effectiveness levels, the security and toxicity 
profiles that continue to improve with the development of new technologies should not be neglected. 
In addition to data that has been widely reported in the literature on the adverse events associated 
with innovative therapies for metastatic melanoma, this work has tried to quantify the economic 
weight associated with the most severe immune-related adverse events (grade ≥ 3) in patients affected 
by metastatic melanoma who submitted to either anti-CTLA-4, new anti-PD1 or combined (CTLA4 
+ anti-PD1) therapies. 
Obviously, this work has limitations in the model. First, the eligibility criteria that were used 
to determine inclusion in the systematic review resulted in the inclusion of different types of studies. 
This difference is due to the ways in which these studies were conducted. Therefore, within these 
analyses, estimates coming from prospective, retrospective or descriptive studies have been included. 
This choice has been made to collect the greatest amount of information concerning immune-related 
adverse events, as immuno-oncology therapies represent an innovation in oncology, especially for 
late-stage patients. Therefore, the literature in this regard is not extensive. Consequently, the second 
limitation of this work is the scarce availability of studies, specifically for pembrolizumab and for 
combination therapy, for which only two works are available, one for pembrolizumab and one for 
combination therapy. A third limitation concerns the cost estimates associated with each adverse 
event. These estimates have been obtained, when possible, from the literature. In particular, they have 
been obtained from two studies that estimated the costs associated with the management of adverse 
events in patients with metastatic melanoma when treated with drugs such as dacarbazine or DTIC, 
temozolomide, fotemustine, IL-2, ipilimumab, vemurafenib, dabrafenib, and trametinib, in the study 
by Wheler et al., while the study by Vouk et al. considers only the costs associated with the 
management of immune-related adverse events that are related to ipilimumab. For both articles, the 
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cost data are for 2013 (actualized at 2014 in the work of Wheler), and they were calculated using the 
national (Vouk) and regional (Wheler) DRG tariffs for hospitalizations, the tariffs supplied by 
AgneNaS (Wheler) and those associated with specialist services (Vouk) for outpatient costs. The cost 
estimates that have not been detected through the systematic review of the literature have been 
obtained by attempting to recreate, together with the support of expert clinicians, the therapeutic and 
monitoring path that would be associated with a patient experiencing a specific adverse event among 
those considered in the specific case study. 
 
Conclusions 
Despite the above indicated limitations, this study may be a useful tool for understanding the 
economic burden of the management of irAEs associated with patients affected by metastatic 
melanoma. 
Knowing the economic dimension of the toxicity linked to immuno-oncology therapies 
represents an important element to evaluate the cost-effectiveness associated with an innovative drug. 
 Certainly, the experience of the centre may lessen the economic burden of toxicity 
management by implementing an early identification and management system for adverse events, 
thereby enabling earlier and easier patient recovery, without hospitalization. In addition to this, the 
treatment would not be interrupted, and the desired clinical outcome would be obtained, with the 
additional benefit of cost-effective patient treatment. 
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